Preliminary Study of Effectiveness and Safety of Prasaprohyai Extract in Patients with Moderate to Severe Allergy Rhinitis
Article Sidebar
Main Article Content
Abstract
Objective: To preliminarily study the effectiveness and safety of 300 mg prasaprohyai extract capsules in a small group pf patients with moderate to severe allergic rhinitis. Method: The study design was a quasi-experimental study in 20 volunteers with moderate to severe symptoms of allergic rhinitis such as nasal congestion, itchy nose, sneezing and runny nose. Volunteers orally received prasaprohyai extract capsules 100 mg after the meal three times a day for 6 weeks. The study assessed preliminary effectiveness from the changes after taking the drug of the Total Nasal Symptom Score, nasal cross-sectional area and volume as measured by acoustic rhinometry and quality of life measured by the RCQ-36. The study also assessed safety by history taking for side effects and liver and renal function test. Results: After taking prasaprohyai extract for 6 weeks, subjects had a significantly reduced nasal symptoms score from 6.40±1.00 in week 0 to 4.15±1.98 in week 6. Quality of life improved with score on impact of disease significantly decreasing from 3.10±.45 to 2.50±.89. Cross-sectional area and volume of nasal cavity tended to increase but had no significant difference. History taking of side-effects revealed one volunteer with belching. All volunteers showed normal liver and renal function tests. Conclusion: The preliminary results of this study could be used to support the conduct of clinical trial in phase 2 for further investigation of effectiveness and safety.
Article Details
ผลการวิจัยและความคิดเห็นที่ปรากฏในบทความถือเป็นความคิดเห็นและอยู่ในความรับผิดชอบของผู้นิพนธ์ มิใช่ความเห็นหรือความรับผิดชอบของกองบรรณาธิการ หรือคณะเภสัชศาสตร์ มหาวิทยาลัยสงขลานครินทร์ ทั้งนี้ไม่รวมความผิดพลาดอันเกิดจากการพิมพ์ บทความที่ได้รับการเผยแพร่โดยวารสารเภสัชกรรมไทยถือเป็นสิทธิ์ของวารสารฯ
References
Kimihiro O, Yuichi K, Keniichi I, Tadao E, Yoshitaka O, Hideyuki K, Harumi S, Shigeharu F, Keisuke M and the Japanese Society of Allergology. Japanese guidelines for allergic rhinitis 2017. Allergol Int 2017 ; 66: 205-19.
Kirtsreesakul V. The prevalence of rhinosinusitis in allergic rhinitis. Songklanagarind Medical Journal. 2006; 24: 299-304.
Bunnag C, Jareoncharsri P, Tantilipikorn P, Vichya nond P, Pawankar R. Epidemiology and current status of allergic rhinitis and asthma in Thailand - ARIA Asia-Pacific Workshop report. Asian Pac J Allergy Immunol. 2009; 27: 79-86.
Mukta O. Self-care Behavior in patients with allergic rhinitis at Phatthalung Hospital. Region 11 Medical Journal. 2015; 29: 615-20.
Chinratanapisit S, Suratannon N, Pacharn P, Sritipsu kho P, Vichyanond P. Prevalence and risk factors of allergic rhinitis in children in Bangkok area. Asian Pac J Allergy Immunol. 2019; 37: 232-9.
Thai Rhinological Society. Clinical practice guidelines of Thai allergic rhinitis pateints (update 2011) [on line]. 2011 [cited Feb 24, 2020]. Available from www.rcot.org/datafile/_file/_doctor/88b81f499ea324fd1c861b51bbb2fcbd.pdf
Ministry of Health, Thailand. National list of essential medicines 2013. [online]. 2013 [cited Feb 24, 2020]. Available from: drug.fda.moph.go.th:81/nle m.in.th/.
Mukkasombut N, Chanvimalueng W, Makchuchit S, Itharat A. Correlation of biological activities on different extraction period times and stability study of Pra-sa-prao-hyai remedy. Thammasat Medical Journal 2013; 13: 504-12.
Mukkasombut N, Pipatrattanaseree W, Itharat A. Validation of HPLC method for the determination of anti-allergic compounds in ethanolic extract of prasaprohyai remedy, a Thai traditional medicine. Thammasat Medical Journal 2020; 20: 74-83.
Makchuchit S, Ruangnoo S, Itharat A. Investigation of anti-allergic and anti-inflammatory activities of Prasaprohyai ethanolic extract under forced degradation and accelerated storage conditions. Thammasat Medical Journal 2019; 19: 371-84.
Plengsuriyakarn T, Viyanant V, Eursitthichai V, Picha P, Kupradinun K, Itharat A, et al. Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. BMC Complement Altern Med 2012; 12: 23. doi: 10.1186/1472-6882-12-23.
Siriruthawong S. Chronic toxicity testing for Prasa prayai remedy extract. In: Itharat A, editor. Drug development on Prasarauyai remedy extract for allergic diseases. Pathumtani: Thammasat Univer- sity; 2016.
Mukkasombut N. Comparison of efficacy between pra-sa-prao-hyai powder and loratadine in allergic rhinitis patients [dissertation]. Pathumtani: Thamma sat University; 2013.
Mukkasombut N, Chanvimalueng W, Itharat A, Budsaba K, Ooraikul B. Clinical trial phase I of prasaprohyai extract capsules. J Med Assoc Thai 2020; 103: 94.
Thai Pharmacopoeia Commission. Thai herbal Phar macopoeia. Nonthaburi: Department of Medical Sciences 2018; 623-754.
Komoltri C. Sample size calculation. Journal of Mental Health of Thailand 2012; 20: 192-8.
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guide lines-2016 revision. J Allergy Clin Immunol. 2017; 140: 950-8. doi:10.1016/j.jaci.2017.03.050
Ellis AK, Soliman M, Steacy L, et al. The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies. Allergy Asthma Clin Immunol. 2015; 11: 16. doi:10.1186/s13223-015-0082-0
Bunnag C, Leurmarnkul W, Jareoncharsri P, et al. Development of a health-related quality of life ques- tionnaire for Thai patients with rhinoconjunc tivitis. Asian Pac J Allergy Immunol. 2004; 22: 69-79.
Thanasumpun T, Assanasen P. Nasal obstruction. [online]. 2017 [cited May 18, 2020]. Available from www.rcot.org/pdf/Nasal_Obstruction06-10-2017.pdf
Food and Drug Administration. Allergic rhinitis: Deve loping drug products for treatment guidance for industry. [online]. 2018 [cited May 18, 2020]. Available from: www.fda.gov/media/71158/down load.
Ungkhara G, Chanasriyotin C, Teerasuwanajuk N. The mucociliary function and nasal obstructive symptoms in allergic rhinitis patients. Vajira Medical Journal. 2016; 60: 15-22.
Tunsaringkarn T, Palanuvej C, Rungsiyothin A, et al . Pharmacognostic specification of Kaempferia galanga Rhizome in Thailand. Journal of Health Research. 2007; 21: 207-14
Tantilipikorn P, Saisombat P, Phonpornpaiboon P, Pinkaew B, Lermankul W, Bunnag C. Minimal clinically important difference for the rhinoconjunc tivitis quality of life questionnaire in allergic rhinitis in Thai population. Asia Pac Allergy. 2019; 9: e6.
